Company Performance - Integer (ITGR) reported quarterly earnings of $1.55 per share, missing the Zacks Consensus Estimate of $1.57 per share, but showing an increase from $1.3 per share a year ago, representing an earnings surprise of -1.27% [1] - The company posted revenues of $476.49 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.87%, compared to year-ago revenues of $436.2 million [2] - Over the last four quarters, Integer has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Integer shares have lost about 12.6% since the beginning of the year, while the S&P 500 has gained 8.1% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $1.67 for the coming quarter and $6.33 for the current fiscal year [7] - The current Zacks Rank for Integer is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Integer belongs, is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - iRadimed (IRMD), another company in the same industry, is expected to report quarterly earnings of $0.45 per share, reflecting a year-over-year change of +7.1% [9]

Core Viewpoint - iRadimed (IRMD) reported quarterly earnings of $0.42 per share, slightly missing the Zacks Consensus Estimate of $0.43 per share, but showing an increase from $0.36 per share a year ago [1][2] Financial Performance - The company posted revenues of $19.51 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.26%, compared to $17.6 million in the same quarter last year [2] - Over the last four quarters, iRadimed has exceeded consensus revenue estimates four times [2] Stock Performance - iRadimed shares have declined approximately 2.8% since the beginning of the year, while the S&P 500 has seen a decline of 3.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.45 on revenues of $20.31 million, and for the current fiscal year, it is $1.79 on revenues of $80.81 million [7] - The trend of estimate revisions for iRadimed is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]